place

North Chicago Community High School

North Chicago, IllinoisPublic high schools in IllinoisSchools in Lake County, Illinois

North Chicago Community High School, also known as North Chicago and NCCHS, is a public four-year high school located in North Chicago, Illinois, a northern suburb of Chicago, in the United States. It is part of North Chicago School District 187. Due to its proximity to the Naval Station Great Lakes, the school serves military families, resulting in a slightly higher than average mobility rate.

Excerpt from the Wikipedia article North Chicago Community High School (License: CC BY-SA 3.0, Authors).

North Chicago Community High School
17th Street,

Geographical coordinates (GPS) Address External links Nearby Places
placeShow on map

Wikipedia: North Chicago Community High SchoolContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 42.3269 ° E -87.8539 °
placeShow on map

Address

North Chicago Community High School

17th Street
60064
Illinois, United States
mapOpen on Google Maps

linkWikiData (Q7054801)
linkOpenStreetMap (354228365)

Share experience

Nearby Places

AbbVie
AbbVie

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab) ($14 billion in 2023 revenues, 27 percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. It developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7 billion in 2023 revenues), Imbruvica to treat cancer ($3.6 billion in 2023 revenues), Rinvoq to treat arthritis ($4 billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3 billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7 billion in 2023 revenues), and Mavyret to treat Hepatitis C ($1.4 billion in 2023 revenues).: 39–40  The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.: 34  In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.